As most TC tumours contain wild type TP53, including all our TC PDX models, the efficacy of RG7388, another MDM2 inhibitor with superior potency and selectivity compared to nutlin-3a, was tested in two different doses in TC1. The gene discussed is MDM2; the disease is neoplasm.